Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus plus everolimus in elderly de novo kidney transplant recipients
2015-005640-34Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus and everolimus in Transplant rejection prophylaxis, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Tacrolimus AUC24, Tacrolimus Cmin and 9 more. Started Jan 2018; status: completed.
02
Drugs
tacrolimuseverolimus
03
Conditions
Transplant rejection prophylaxis
Beyond the preview
Go deeper on 2015-005640-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005640-34.